SCHEMBL15414908

SCHEMBL15414908

O=C(CBr)c1cc(F)ccc1OC(F)F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.43
PDE4A P27815 4/20 0.39
PDE4B Q07343 4/20 0.39
PDE4C Q08493 4/20 0.39
PDE4D Q08499 4/20 0.39
PKM P14618 1/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
HPGDS O60760 1/20 0.38
PTGER1 P34995 2/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
KMT2A Q03164 1/20 0.36
CYP11B1 P15538 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23611727 0.83 KEAP1 (0.50) PDE4APDE4BPDE4CPDE4DPKM
SCHEMBL2097092 0.83 ALDH1A1 (0.43) PDE4APDE4BPDE4CPDE4DHTT
SCHEMBL17282253 0.83 MAPT (0.44) PDE4APDE4BPDE4CPDE4DHTT
SCHEMBL9196847 0.82 PTPN1 (0.46) PTPN1PDE4APDE4BPDE4CPDE4D
SCHEMBL30634443 0.82 PTPN1 (0.46) PTPN1PDE4APDE4BPDE4CPDE4D
SCHEMBL2097494 0.81 HPGDS (0.54) PTPN1PKMSMN1; SMN2HPGDSKMT2A
SCHEMBL29586157 0.81 HPGDS (0.54) PTPN1PKMSMN1; SMN2HPGDSKMT2A
SCHEMBL18398482 0.79 IRAK4 (0.45) HTTALDH1A1SMN1; SMN2CES2CES1
SCHEMBL22646881 0.79 HTT (0.44) PKMHTTALDH1A1SMN1; SMN2CES2
SCHEMBL30688864 0.79 HTT (0.44) PKMHTTALDH1A1SMN1; SMN2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872508-B1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-08-29 EP disclosed
US-9309243-B2 Imidazopyridine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2016-04-12 US disclosed
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity UCB Biopharma SPRL a corporation 2015-07-23 US disclosed
EP-2872508-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
WO-2014009295-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203486-A1 Imidazopyridine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, IL1A PTPN1 513/4885PDE4A 143/4885PDE4B 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.